ProMIS Neurosciences Inc. (PMN)

Over the past six months, ProMIS Neurosciences announced full-year 2025 financial results and the full enrollment of its PRECISE-AD Phase 1b trial for PMN310, with interim data expected in early Q3 2026. The company unveiled precision vaccines for ALS and Parkinson's Disease and presented data at the Alzheimer's Disease/Parkinson's Disease 2026 International Conference. ProMIS Neurosciences participated in the Guggenheim Emerging Outlook: Biotech Summit 2026 and secured up to $175 million in private placement financing, extending its cash runway through 2027. The company exceeded its target enrollment for the PRECISE-AD Phase 1b clinical trial of PMN310, and its price target was increased by analysts. HC Wainwright & Co. and Guggenheim maintained their "Buy" recommendations for PMN. PMN's stock price declined by 24.97% between April 8, 2025, and April 7, 2026, underperforming the US Biotechs industry and the US Market. However, in the last three months, PMN outperformed the market, returning +53.6% compared to a -3.3% return in the SPY ETF.

ProMIS Neurosciences, as a clinical-stage biotechnology company, does not experience traditional demand seasonality. Demand for its product candidates is driven by clinical trial progress, regulatory approvals, and the medical need for neurodegenerative disease treatments.

ProMIS Neurosciences, Inc. is a clinical-stage biotechnology company focused on developing therapeutic antibodies and vaccines that selectively target toxic misfolded proteins involved in neurodegenerative diseases like Alzheimer's, ALS, FTD, MSA, and Parkinson's. Their EpiSelect™ platform identifies Disease Specific Epitopes (DSEs) to create highly selective antibodies, potentially improving efficacy and tolerability. Key product candidates include PMN310 for Alzheimer's (with Fast Track Designation), PMN267 for ALS, and PMN442 for MSA. They are also developing vaccines like PNM440 for synucleinopathies and PMN311 for Alzheimer's.

ProMIS Neurosciences is incorporated in Ontario, Canada, with its head office in Toronto, Ontario, and offices in Cambridge, Massachusetts, USA.

ProMIS Neurosciences has a consensus rating of "Moderate Buy" with an average rating score of 2.50 and a consensus price target of $42.67. The company's stock has underperformed the US Biotechs industry and the broader US Market over the past year, with increased short interest indicating decreased investor sentiment. Positive factors include the successful enrollment of the Phase 1b trial for PMN310, the favorable safety profile of PMN310, securing private placement financing, and the FDA's Fast Track Designation for PMN310.

As of April 9, 2026, ProMIS Neurosciences has 18 institutional owners and shareholders holding a total of 264,549 shares, representing 50.13% institutional ownership. Major institutional owners include Ally Bridge Group, Sphera Funds Management Ltd., and UBS Group AG.